BioCentury | Sep 30, 2019
Company News

Sept. 30 Company Quick Takes: Lumos-NewLink, Simcere-JW, Ocugen-CanSino, Chamishi’s launch, and AbbVie-Allergan

...is OrbiMed Advisors venture partner Jim Sullivan. Ocugen partners with CanSino on retinal gene therapy Ocugen Inc....
...3 group E member 3 BioCentury Staff AbbVie Inc. Allergan Inc. Simcere Pharmaceutical Group JW Pharmaceutical Corp. Q-State Biosciences Inc. CanSino Biologics Inc. Ocugen Inc. URC-102 The...
BioCentury | Apr 11, 2019
Company News

Ocugen to go public via Histogenics reverse merger

...form a public company focused on discovering, developing and commercializing therapies for rare eye diseases. Ocugen Inc....
...own about 90% of the resulting company, which will trade on NASDAQ and be named Ocugen Inc....
...will own about 10%. The transaction is expected to close in late 2Q19 or 3Q19. Ocugen...
BioCentury | Aug 13, 2018
Company News

Management tracks: FDA, Allergan

...Bing Li as CEO. He was managing director at Fosun International Ltd. (HKSE:656). Ophthalmology company Ocugen Inc....
BioCentury | Apr 13, 2018
Clinical News

Ocugen reports Phase II data for dry eye disease candidate

...Dry Eye (SANDE) scores and conjunctival and corneal staining with lissamine green, compared with placebo. Ocugen...
...an upcoming meeting. The double-blind, U.S. trial enrolled about 90 patients with dry eye disease. Ocugen...
...a relatively selective adrenergic receptor alpha 2 (ADRA2) agonist, combined with loteprednol etabonate, a corticosteroid. Ocugen Inc....
BioCentury | Jun 16, 2017
Financial News

Ocugen raises $7.5M in series B

...Ophthalmology company Ocugen Inc. (Malvern, Pa.) raised $7.5 million in a series B round led by Abdi...
...JSC Lancaster Group on June 15. Existing individual investors also participated. Ocugen Inc. , Malvern, Pa. Alex Himes Ocugen Inc....
BioCentury | Dec 16, 2016
Financial News

Ocugen completes venture round

...series A round from EB5 Life Sciences and former pharma executives. Ocugen Inc. , Aurora, Colo. Alicia Parker Ocugen Inc....
BioCentury | Feb 22, 2016
Company News

University of Illinois at Chicago, Ocugen deal

...The university granted Ocugen exclusive, worldwide rights to develop and commercialize OCU300 . The repurposed undisclosed...
...in a post hoc analysis of an exploratory observational study in ocular graft-versus-host disease (GvHD). Ocugen...
...data on safety and efficacy from scientific literature or from previously approved products. In 2017, Ocugen...
BioCentury | Jun 16, 2014
Clinical News

OCU100 regulatory update

...and SFRS1-interacting protein ( PSIP1 ; LEDGF ; p75; LEDGF/p75 ) fragment 1-326, in 2015. Ocugen...
...worldwide rights from the University of Colorado to all assets related to LEDGF, including OCU100. Ocugen Inc....
BioCentury | Jun 16, 2014
Company News

Ocugen, University of Colorado deal

...The university granted Ocugen exclusive, worldwide rights to assets related to PC4 and SFRS1-interacting protein...
...in development for wet age-related macular degeneration (AMD). The parties declined to disclose financial terms. Ocugen Inc....
BioCentury | Dec 3, 2001
Company News

InSite, Quest Diagnostics sales and marketing update

DGX will exclusively provide laboratory testing services in the U.S. for one year for ISV's marketed Ocugene genetic test for glaucoma. InSite Vision Inc. (ISV), Alameda, Calif. Quest Diagnostics Inc. (DGX), Teterboro, N.J. Business: Ophthalmic...
Items per page:
1 - 10 of 11
BioCentury | Sep 30, 2019
Company News

Sept. 30 Company Quick Takes: Lumos-NewLink, Simcere-JW, Ocugen-CanSino, Chamishi’s launch, and AbbVie-Allergan

...is OrbiMed Advisors venture partner Jim Sullivan. Ocugen partners with CanSino on retinal gene therapy Ocugen Inc....
...3 group E member 3 BioCentury Staff AbbVie Inc. Allergan Inc. Simcere Pharmaceutical Group JW Pharmaceutical Corp. Q-State Biosciences Inc. CanSino Biologics Inc. Ocugen Inc. URC-102 The...
BioCentury | Apr 11, 2019
Company News

Ocugen to go public via Histogenics reverse merger

...form a public company focused on discovering, developing and commercializing therapies for rare eye diseases. Ocugen Inc....
...own about 90% of the resulting company, which will trade on NASDAQ and be named Ocugen Inc....
...will own about 10%. The transaction is expected to close in late 2Q19 or 3Q19. Ocugen...
BioCentury | Aug 13, 2018
Company News

Management tracks: FDA, Allergan

...Bing Li as CEO. He was managing director at Fosun International Ltd. (HKSE:656). Ophthalmology company Ocugen Inc....
BioCentury | Apr 13, 2018
Clinical News

Ocugen reports Phase II data for dry eye disease candidate

...Dry Eye (SANDE) scores and conjunctival and corneal staining with lissamine green, compared with placebo. Ocugen...
...an upcoming meeting. The double-blind, U.S. trial enrolled about 90 patients with dry eye disease. Ocugen...
...a relatively selective adrenergic receptor alpha 2 (ADRA2) agonist, combined with loteprednol etabonate, a corticosteroid. Ocugen Inc....
BioCentury | Jun 16, 2017
Financial News

Ocugen raises $7.5M in series B

...Ophthalmology company Ocugen Inc. (Malvern, Pa.) raised $7.5 million in a series B round led by Abdi...
...JSC Lancaster Group on June 15. Existing individual investors also participated. Ocugen Inc. , Malvern, Pa. Alex Himes Ocugen Inc....
BioCentury | Dec 16, 2016
Financial News

Ocugen completes venture round

...series A round from EB5 Life Sciences and former pharma executives. Ocugen Inc. , Aurora, Colo. Alicia Parker Ocugen Inc....
BioCentury | Feb 22, 2016
Company News

University of Illinois at Chicago, Ocugen deal

...The university granted Ocugen exclusive, worldwide rights to develop and commercialize OCU300 . The repurposed undisclosed...
...in a post hoc analysis of an exploratory observational study in ocular graft-versus-host disease (GvHD). Ocugen...
...data on safety and efficacy from scientific literature or from previously approved products. In 2017, Ocugen...
BioCentury | Jun 16, 2014
Clinical News

OCU100 regulatory update

...and SFRS1-interacting protein ( PSIP1 ; LEDGF ; p75; LEDGF/p75 ) fragment 1-326, in 2015. Ocugen...
...worldwide rights from the University of Colorado to all assets related to LEDGF, including OCU100. Ocugen Inc....
BioCentury | Jun 16, 2014
Company News

Ocugen, University of Colorado deal

...The university granted Ocugen exclusive, worldwide rights to assets related to PC4 and SFRS1-interacting protein...
...in development for wet age-related macular degeneration (AMD). The parties declined to disclose financial terms. Ocugen Inc....
BioCentury | Dec 3, 2001
Company News

InSite, Quest Diagnostics sales and marketing update

DGX will exclusively provide laboratory testing services in the U.S. for one year for ISV's marketed Ocugene genetic test for glaucoma. InSite Vision Inc. (ISV), Alameda, Calif. Quest Diagnostics Inc. (DGX), Teterboro, N.J. Business: Ophthalmic...
Items per page:
1 - 10 of 11